CRICKi005-A

iFCI004

General

Cell Line

hPSCreg name CRICKi005-A
Cite as:
CRICKi005-A (RRID:CVCL_C3R0)
Alternative name(s)
iFCI004
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
CRICKi006-A
(iFCI005)
Donor diseases:
spinal muscular atrophy
UCSCi001-A
(SII-1802)
Donor diseases:
Amyotrophic Lateral Sclerosis
SAPi004-A
(ALS III, TDP43-A382T/A382T, ALS III-TDP43-A382T/A382T)
Donor diseases:
Amyotrophic lateral sclerosis
STBCi320-A
(SFC031-03-03)
Donor diseases:
Parkinson disease
LUMCi002-A
(113-6, LUMC0113iATAX06)
Donor diseases:
Spinocerebellar Ataxia Type 1
STBCi295-B
(SFC847-03-08)
Donor diseases:
Parkinson disease
LUMCi002-B
(113-7, LUMC0113iATAX07)
Donor diseases:
Spinocerebellar Ataxia Type 1
LCPHi003-A
Donor's gene variants:
LRP10
Donor diseases:
Parkinson Disease
LUMCi002-C
(113-8, LUMC0113iATAX08)
Donor diseases:
Spinocerebellar Ataxia Type 1
LCSBi013-A
(GL2)
Donor diseases:
Parkinson Disease
UMi036-A
(ND34263)
Donor diseases:
Parkinson Disease
HIHDNDi001-A
(A30P-3, SNCA3, Tue_020_A)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
ZZUi013-A
(ZZU-iPS-AD-MEOX2-001)
Donor diseases:
obsolete_Alzheimer's disease
HIHDNDi001-B
(A30P-4, SNCA4, Tue_020_B)
Donor's gene variants:
SNCA, SNCA, SNCA
Donor diseases:
autosomal dominant Parkinson disease 1
ZZUi026-A
(ZZU-iPS-SCA3-003)
Donor diseases:
Spinocerebellar Ataxia Type 3
UTSWi001-A
(FA1)
Donor diseases:
Friedreich Ataxia
DANi002-C
(GBA-002-C3)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
ZZUi027-A
(ZZU-iPS-PD-RAB39b-002)
Donor diseases:
Parkinson Disease
DANi003-H
(GBA-003-C8)
Donor's gene variants:
GBA
Donor diseases:
Parkinson Disease
DANi005-A
(LRRK2-GBA-005-C1)
Donor's gene variants:
GBA, LRRK2
Donor diseases:
Parkinson Disease
LCSBi001-A
(VPS35 1_2)
Donor diseases:
obsolete_Parkinson's disease
DANi007-A
(PINK1-007-C1)
Donor's gene variants:
PINK1
Donor diseases:
Parkinson Disease
FDHSi002-A
(FDITBRi002-A)
Donor diseases:
Parkinson Disease
DANi008-F
(SNCA-008-C6)
Donor's gene variants:
SNCA
Donor diseases:
Parkinson Disease
NYSCFi003-A
(CO0002-01-SV-003)
Donor diseases:
Alzheimer's Disease
SAPi002-A
(ALS I, ALS I–FUS-R514S/wt, FUS-R514S/wt)
Donor diseases:
amyotrophic lateral sclerosis
ZZUi012-A
(ZZU-iPS-PFBC-SLC20A2-001)
Donor diseases:
Bilateral striopallidodentate calcinosis
ZZUi030-A
(ZZU-iPS-SPG7-001)
Donor diseases:
Spastic paraplegia type 7
ZZUi024-A
(ZZU-iPS-AD-APP-002)
Donor diseases:
Alzheimer's Disease
LCPHi001-A
Donor's gene variants:
GBA
Donor diseases:
obsolete_Parkinson's disease
OSRi001-A
(PD-OPA1-A495V#72)
Donor diseases:
Parkinson Disease
ZZUi017-A
(ZZU-iPS-SCA6-001)
Donor diseases:
Spinocerebellar Ataxia Type 6
CSBZZUi001-A
(CSBZZU_PS1_001)
Donor diseases:
Alzheimer disease
Last update 12th December 2022
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator The Francis Crick Institute Limited (CRICK)

External Databases

BioSamples SAMEA112226452
Cellosaurus CVCL_C3R0
Wikidata Q116048788

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation.
Synonyms
  • spinal muscular atrophy

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
The KaryoStat™ assay allows for digital visualization of chromosome aberrations with a resolution similar to g-banding karyotyping by relying on 150k SNP probes across the human genome. The size of structural aberration that can be detected is > 2 Mb for chromosomal gains and > 1 Mb for chromosomal losses. The assay enables the detection of aneuploidies, submicroscopic aberrations, and mosaic events.
Karyotyping method: G-Banding

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA112224409

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? No
If you do not hold the Donor Consent Form, do you know who does? Yes
Contact information / weblink https://www.ucl.ac.uk/child-health/mrc-cnmd-biobank-london
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. anonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? No
Does consent permit unforeseen future research, without further consent? Yes
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? Yes
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? Yes
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? Yes

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
How may genetic information associated with the cell line be accessed? No information
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? The London – West London & GTAC Research Ethics Committee (formerly known as the Hammersmith, Queen Charlotte's and Chelsea Research Ethics Committee).
Approval number 08ND17
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used?

hIPSC Derivation

General

Source cell type
Synonyms
  • fibroblast
  • Fibroblasts
  • Fibroblast
  • FIBROBLAST
show more synonyms

Reprogramming method

Vector type None

Vector free reprogramming

Type of used vector free reprogramming factor(s)
mRNA
mRNA

Other

Selection criteria for clones Manually picked by best morphology
Derived under xeno-free conditions
No
Derived under GMP?
No
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
Gentle Cell Dissociation Reagent
O2 Concentration 5 %
CO2 Concentration 5 %
Medium mTeSR™ 1
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
POU5F1 (OCT-4)
Yes
Method documentation
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology
Mesoderm
Ont Id: UBERON_0000926
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology
Ectoderm
Ont Id: UBERON_0000924
In vitro spontaneous differentiation
In vitro directed differentiation
Scorecard
Morphology

Microbiology / Virus Screening

HIV 1 Negative
HIV 2 Negative
Hepatitis B Negative
Hepatitis C Negative
Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
The KaryoStat™ assay allows for digital visualization of chromosome aberrations with a resolution similar to g-banding karyotyping by relying on 150k SNP probes across the human genome. The size of structural aberration that can be detected is > 2 Mb for chromosomal gains and > 1 Mb for chromosomal losses. The assay enables the detection of aneuploidies, submicroscopic aberrations, and mosaic events.
Karyotyping method: G-Banding

Other Genotyping (Cell Line)